
|Articles|July 1, 2003
Antigen Activation
Chicago - Results from an ongoing phase II clinical trial point out that electrochemotherapy followed by low-dose interleukin-2 (IL-2) (Proleukin) produces a clinical response in a subset of patients with disseminated malignant melanoma, Julie Gehl, M.D., said at the 39th annual meeting of the American Society of Clinical Oncology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 2
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















